All In Biotech

Drug Trial Radar · NCT07072611

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

A Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 14, 2025

Primary completion

Dec 27, 2025

Study completion May 5, 2026

Sponsor

Lead sponsor
Noxopharm LimitedIndustry
Sponsor type
Industry
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to investigate the safety and tolerability of the topical application of SOF-SKN in healthy volunteers. The study will be divided into part 1 and part 2. Part 1, is a single ascending dose (SAD) design, while Part 2 is a multiple ascending dose (MAD) design.

Conditions

  • Cutaneous Lupus Erythematosus

Interventions

  • SOF-SKN 0.25%Drug

    cream for topical application

  • SOF-SKN 0.5%Drug

    cream for topical application

  • SOF-SKN 1%Drug

    cream for topical application

  • SOF-SKN 2%Drug

    cream for topical application

  • PlaceboDrug

    cream for topical application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Target Toxicities after a single treatmentTime frame: 4 days -3 days after last application of topical treatment
  2. Percentage of Target Toxicities after two-week treatmentTime frame: 17 days - 3 days after last dose of treatment
  3. Percentage of Adverse events (AEs) after a single treatmentTime frame: 4 days -3 days after last application of topical treatment
  4. Percentage of Adverse events (AEs) after two-week treatmentTime frame: 17 days - 3 days after last dose of treatment
  5. Percentage of Serious Adverse events (SAEs) after a single treatmentTime frame: 4 days -3 days after last application of topical treatment
  6. Percentage of serious Adverse events (SAEs) after two-week treatmentTime frame: 17 days - 3 days after last dose of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Doherty Clinical Trials

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.